Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer’s disease
Abstract
Purpose Although( 18)F-fluorodeoxyglucose (FDG) PET is an established imaging technique to assess brain glucose utilisation, accurate measurement of tracer concentration is confounded by the presence of partial volume effect (PVE) due to the limited spatial resolution of PET, which is particularly true in atrophic brains such as those encountered in patients with Alzheimer's disease (AD). Our aim was to investigate the effects of PVE correction on FDG PET in conjunction with voxel-based morphometry (VBM) in patients with mild AD. Methods Thirty-nine AD patients and 73 controls underwent FDG PET and MRI. The PVE-corrected grey matter PET images were obtained using an MRI-based three-compartment method. Additionally, the results of PET were compared with grey matter loss detected by VBM. Results Before PVE correction, reduced FDG uptake was observed in posterior cingulate gyri (PCG) and parieto-temporal lobes (PTL) in AD patients, which persisted after PVE correction. Notably, PVE correction revealed relatively preserved FDG uptake in hippocampal areas, despite the grey matter loss in medial temporal lobe (MTL) revealed by VBM. Conclusion FDG uptake in PCG and PTL is reduced in AD regardless of whether or not PVE correction is applied, supporting the notion that the reduced FDG uptake in these areas is not the result of atrophy. Furthermore, FDG uptake by grey matter tissue in the MTL, including hippocampal areas, is relatively preserved, suggesting that compensatory mechanisms…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Individuals with MCI and early AD have diminished regional brain uptake of 2-DG, as measured by FDG-PET, before MCI-AD conversion, brain atrophy, or neurodegenerative changes.
“Individuals with MCI and early AD have diminished regional brain uptake of 2-DG, as measured by FDG-PET, before MCI-AD conversion, brain atrophy, or neurodegenerative changes (268, 345, 424, 425, 517).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [517]
Cites
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation.
Hyman, B. T., Van Hoesen, G. W., Damasio, A. R., & Barnes, C. L. (1984) · Science · doi:10.1126/science.6474172 · Cited by 2,268 · see citing works
Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease
West, M. J., Coleman, P. D., Flood, D. G., & Troncoso, J. C. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92338-8 · Cited by 1,267 · cited 1× · see citing works
“(Height threshold 0.05, corrected for multiple comparison) Eur J Nucl Med Mol Imaging (2007) 34:1658–1669 1667 severity of disease [ 42 , 43].”
BackgroundInfluentialBall, M. J. (1977) · Acta Neuropathologica · doi:10.1007/bf00692056 · Cited by 639 · see citing works
Quantitative assessment of cortical synaptic density in Alzheimer's disease
Scheff, S. W., DeKosky, S. T., & Price, D. A. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90059-9 · Cited by 446 · see citing works
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Petrella, J. R., Coleman, R. E., & Doraiswamy, P. M. (2003) · Radiology · doi:10.1148/radiol.2262011600 · Cited by 427 · see citing works
Altered glucose metabolism in the hippocampal head in memory impairment
Ouchi, Y., Nobezawa, S., Okada, H., Yoshikawa, E., Futatsubashi, M., & Kaneko, M. (1998) · Neurology · doi:10.1212/wnl.51.1.136 · Cited by 85 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · see citing works
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076 · see citing works
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969 · see citing works
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,294 · see citing works
The blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767 · see citing works
The blood-brain barrier in aging and neurodegeneration
Knox, E. G., Aburto, M. R., Clarke, G., Cryan, J. F., & O’Driscoll, C. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01511-z · Cited by 738 · see citing works
Vascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711 · see citing works
Age-associated Physiological and Pathological Changes at the Blood-Brain Barrier: A Review
Erdő, F., Denes, L., & de Lange, E. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16679420 · Cited by 426 · see citing works
Microglia–blood vessel interactions: a double-edged sword in brain pathologies
Dudvarski Stankovic, N., Teodorczyk, M., Ploen, R., Zipp, F., & Schmidt, M. H. H. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1524-y · Cited by 301 · see citing works
Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data
Greve, D. N., Svarer, C., Fisher, P. M., Feng, L., Hansen, A. E., Baare, W., Rosen, B., Fischl, B., & Knudsen, G. M. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.12.021 · Cited by 264 · see citing works
Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251 · see citing works
FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: A longitudinal study
Initiative, O. B. O. A. D. N., Ou, Y.-N., Xu, W., Li, J.-Q., Guo, Y., Cui, M., Chen, K.-L., Huang, Y.-Y., Dong, Q., Tan, L., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0512-1 · Cited by 155 · see citing works
Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment
Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17718-y · Cited by 163 · see citing works
Dukart, J., Mueller, K., Horstmann, A., Vogt, B., Frisch, S., Barthel, H., Becker, G., Möller, H. E., Villringer, A., Sabri, O., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.09.017 · Cited by 134 · see citing works
- Authors
- Samuraki, M., Matsunari, I., Chen, W.-P., Yajima, K., Yanase, D., Fujikawa, A., Takeda, N., Nishimura, S., Matsuda, H., & Yamada, M.
- Affiliations
- Kanazawa University (JP)
- The Medical and Pharmacological Research Center Foundation (JP)
- Corresponding author
- Matsunari, Ichiro
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2007-05-23
- Volume
- 34
- Issue
- 10
- Pages
- 1658-1669
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2077466632
- Cited by
- 92
- References
- 6
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 2 · 2016: 6 · 2015: 10 · 2014: 6 · 2013: 6 · 2012: 8
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- partial volume correction, FDG-PET, mild Alzheimer's disease, gray matter loss, posterior cingulate cortex, hippocampus, medial temporal lobe atrophy, compensatory mechanisms, brain glucose metabolism
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Image Enhancement, Male, Middle Aged, Neurons, Artifacts, Radiopharmaceuticals, Fluorodeoxyglucose F18, Imaging, Three-Dimensional, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
